Status:
COMPLETED
Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
AbbVie
Conditions:
Hepatocellular Carcinoma
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
In this international collaboration study, the research group will analyze somatic mutations of hepatocellular carcinoma (HCC) developed after sustained virological response (SVR) in patients treated ...
Detailed Description
Method Paired liver tissue samples will be collected from the tumour sections and also from the adjacent non-tumour tissues, for comparison in each individual. The tissues have been collected as part ...
Eligibility Criteria
Inclusion
- Patients with sustained virological response (SVR) after interferon (IFN)-containing or IFN-free treatment, and developed hepatocellular carcinoma (HCC)
- Available liver biopsies from hepatocellular carcinoma and non-HCC tissue
Exclusion
- Co-infection with chronic hepatitis B (HBsAg positive) or HIV infection.
- Liver transplantation prior to treatment-start, leading to SVR.
- Patients with diagnosed HCC prior to treatment-start, leading to SVR.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT03254121
Start Date
January 1 2017
End Date
September 1 2020
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institutet
Stockholm, Sweden